Catharanthus roseus Combined with Ursolic Acid Attenuates Streptozotocin-Induced Diabetes through Insulin Secretion and Glycogen Storage

الملخص EN

Catharanthus roseus (C.

roseus) and ursolic acid (UA) are ayurvedic medicines with multiple pharmacological activities including antidiabetic activity, but till date, no study is available on their combination.

This study documented the antidiabetic efficacy of the combination of C.

roseus and UA in rats.

Rats were divided into six groups.

All groups were given a single dose of Streptozotocin (STZ) at a dose of 50 mg/kg by intraperitoneal route for induction of diabetes, except the normal control group.

Group 1 was treated as a normal control (NC) group and fed with saline water, Group 2 as a Diabetes Control group, Group 3 as a STZ+C.

roseus ethanolic extract (CREE) group at 50 mg/kg p.o., Group 4 as a STZ+UA group orally at 50 mg/kg, Group 5 as a STZ+CREE (25 mg/kg p.o.)+UA (25 mg/kg p.o.) group, and Group 6 as a STZ+Glimepiride (0.1 mg/kg) group.

Diabetes was confirmed after 72 hours by estimation of blood glucose level, and then treatment was given for the next 28 days.

During the course of treatment, plasma insulin and blood glucose were measured regularly at the interval of 7 days.

At the end of the protocol, blood was collected and animals were sacrificed.

The glucose level, insulin level, liver glycogen storage level, and antioxidant enzymes (LPO, CAT, SOD, GPx, GST) were measured.

The blood glucose level in Group 5 significantly (P<0.001) reduced to 98.35±2.45 mg/dl in comparison with that in Group 2 (321.75±5.46 mg/dl).

The level of plasma insulin in Group 5 increased (13.65±0.10 μU/ml) significantly (P<0.01) as compared with that in Group 2 (05.93±0.31 μU/ml).

In Group 5, the level of glycogen in liver was significantly (P<0.01) increased as compared with that in Group 2 rats.

The level of antioxidant enzymes in Group 5 restored toward normal values significantly (P<0.01; P<0.001) as compared with that in Group 2 animals.

These findings suggest that low-dose combination of CREE and UA is effective in the treatment of diabetes.